Key facts
- Novartis and Abogen signed a licensing deal valued at up to $7.8 billion.
- Novartis gains exclusive rights to Abogen's experimental drug ABO2203.
- ABO2203 targets B cells for autoimmune diseases like lupus and rheumatoid arthritis.
- Abogen receives an initial $575 million payment.
- Abogen could earn an additional $7.2 billion based on the drug's success.
Swiss pharmaceutical giant Novartis has entered into a significant licensing agreement with Chinese biotech firm Abogen, potentially worth up to $7.8 billion. The deal grants Novartis exclusive rights to Abogen's experimental drug ABO2203, which targets B cells for the treatment of autoimmune diseases such as lupus and rheumatoid arthritis. Novartis also secures options to license other therapies developed using Abogen's RNA technology.
Under the terms of the agreement, Abogen will receive an initial payment of $575 million. The company stands to earn an additional $7.2 billion if ABO2203 successfully navigates development and gains regulatory approval. This collaboration underscores the growing interest in RNA-based therapies for a range of medical conditions.